CRF receptor agonists
Corticotropin-releasing hormone (CRH), originally named corticotropinreleasing factor (CRF) and occasionally called corticoliberin, is a significant neurohormone of the hypothalamic-pituitary-adrenal (HPA) axis and also an important neurotransmitter released from hypothalamic and extrahypothalamic nuclei in mammals.
Since CRF was first characterized, a growing family of ligands and receptors has been discovered. The mammalian family members include CRF, urocortin I (UCN I), urocortin II (UCN II), also known as stresscopin-related peptide (SRP), and urocortin III (UCN III), also known as stresscopin (SCP), along with two CRF receptors, CRFR1 and CRFR2, and a CRF-binding protein (CRF-BP). Previously it has been suggested that CRF-related peptides could play important roles in the regulation of the endocrine, autonomic and behavioral responses to stress. Although the role of CRF, activating CRFR1, is stimulatory upon stress responsivity, the role of UCN II and UCN III, both acting on CRFR2, appears to be inhibitory upon stress sensitivity. As the only ligand with equally high affinity for both receptors, UCN I's role may be promiscuous.
CRF receptors
CRFRs belong to the class B subtype of G protein-coupled receptors (GPCRs).
CRFR1 and CRFR2 are produced from distinct genes and have several splice variants expressed in various central and peripheral tissues. CRFR1 has α and β isoforms in addition to subtypes designated c-h, which have been detected in human and rodent tissues. Several of these isoforms have been shown to be nonfunctional. CRFR2 is expressed in three functional subtypes, α, β, and γ. Both CRFR2α and CRFR2β have been detected in human and rodents, while CRFR2γ has only been reported in humans. There is nearly 70% identity between CRFR1 and CRFR2 at the aminoacid level. As is consistent with other GPCR family members, the transmembrane and intracellular domains of the CRFRs have the highest homology (over 80% identity). The third intracellular loop is the receptor region thought to interact with the G-proteins for most GPCRs. 4
CRF receptor antagonists
The first CRFR antagonist synthesised and studied was α-helical CRF 9-41, that efficiently blocked CRF-induced adrenocorticotropic hormone (ACTH) secretion and stress-induced locomotor activation, followed by D-Phe CRF 12-41, a more potent antagonist of CRF, than α-helical CRF 9-41. Astressin, a novel CRFR antagonist, was found to be particularly potent at inhibiting the HPA axis. It could reverse the CRF-or stress-induced anxiogenic-like behaviour induced, but it could not prevent, CRF or stressinduced locomotor hyperactivity. CP-154,526 and its structurally related analog antalarmin are selective nonpeptidic CRFR1 antagonists used especially to characterize the central actions of CRFR1s. Both compounds were able to penetrate the blood-brain barrier and antagonize endocrine and behavioural effects of CRF, UCN I or specific stressors. Though results with CP-154,526 may seem confusing, studies with antalarmin may prove promising for future anxiolytic and antidepressant research. Antisauvagine 30 and astressin 2B, structurally derived from sauvagine and astressin, respectively, are selective peptidic CRFR2 antagonists used preferentially to scrutinize the peripheral functions of CRFR2s.
µ µ µ µ Opioid receptor agonists
There are three classical opioid receptors designated µ (MOR), δ (DOR), and κ (KOR), and one orphan opioid-receptor like receptor (ORL) found in the central and peripheral nervous systems of mammals mediating the biological actions of exogenous and endogenous opioids. Until lately, no mammalian peptide was found and proved to be highly selective for MOR. Endomorphin 1 (EM1) and endomorphin 2 (EM2) were the peptides extracted from bovine brain and isolated later in human brain, that were proposed finally as selective endogenous ligands for MOR. Radioimmunological and immunohistochemical analyses revealed that EM immunoreactivities are distributed throughout the human, bovine, and rodent CNS in similar manner that the MORs. The neuroanatomical localization of these peptides reflect their potential participation in many physiological processes, such as antinociception and modulation of stress.
µ µ µ µ Opioid receptors
The MORs belong to the superfamily of heterotrimeric, guanine-nucleotide The activation of the HPA axis is associated with release of CRF, DA and GABA from extrahypothalamic sources of CRF. On one hand, the DA released from the striatum, part of both mesolimbical and nigrostriatal pathways, may mediate the stress-related locomotor hyperactivation; on the other hand the GABA release from the amygdala, part of the extended amygdala circle, may transmit the stress-induced stereotype behaviour of the animals. Thus, our second purpose was to determine the radio-labelled DA and GABA concentrations from superfused striatal and amygdalar slices isolated from rats after in vitro administration of UCNs and EMs.
The participation of the CRFR subtypes and MOR subtypes in these processes is not fully elucidated; brain slices were pretreated in vitro with selective CRFR antagonists, antalarmin (CRFR1 antagonist) and astressin 2B (CRFR2 antagonist) and selective MOR antagonists, naloxonazine (MOR1 and MOR2 antagonist) and β-funaltrexamine (MOR1 antagonist) to clarify the possible physiological and potential therapeutical roles of these receptors and their ligands.
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MATERIALS AND METHODS
Materials
Corticotropin-releasing hormone, CRH (Bachem, Switzerland);
Urocortin I (Bachem, Switzerland), non-selective CRFR agonist;
Urocortin II (Bachem, Switzerland), selective CRFR2 agonist;
Urocortin III (Bachem, Switzerland), selective CRFR2 agonist. α-helical CRF 9-41 (Sigma-Aldrich, Austria), non-selective CRFR antagonist;
Antalarmin (Sigma-Aldrich, Austria), selective CRFR1 antagonist;
Asstressin 2B (Sigma-Aldrich, Austria), selective CRFR2 antagonist.
Endomorphin 1 (Bachem, Switzerland), selective MOR agonist;
Naloxonazine (Bachem, Switzerland), selective MOR antagonist. 
Animals
The animals were kept and handled during the experiments in accordance with the instructions of the University of Szeged Ethical Comittee for the Protection of Animals in Research. Male Wistar rats weighing 150-200 g were used. The rats were kept in their home cages at constant room temperature (23°C) on a standard illumination schedule, with 12-h light and 12-h dark periods (lights on from 6:00 a.m.). Commercial food and tap water were available ad libitum. The rats were allowed a minimum of 7 days to acclimatize before surgery, and, to minimize the effects of nonspecific stress the rats were handled daily.
Surgery
For the intracerebroventricular (ICV) administration of neuropeptides, the rats were implanted with a stainless steel Luer cannula (10 mm long) aimed at the right lateral cerebral ventricle under Nembutal (35 mg/kg, ip) anesthesia. Cannulas were secured to the skull with dental cement and acrylate. The rats were used after a recovery period of at least 5 days. The implantation of the cannula and the isolation of different brain regions were made according to the Stereotaxic Atlas Of The Rat Brain (Pellegrino et al. 1979 ).
Administration
The in vivo administration of CRF agonists or MOR agonists was made ICV through the cannula implanted in the right lateral cerebral ventricles 30 min before the animals were sacrificed. The CRF antagonist α-helical CRF was injected ICV 30 min before MOR agonist treatment. The in vitro administration of CRF agonists was made 12 min before the electrical stimulation of the brain slices. When antagonization of a previous effect was intended, the slices were pretreated with selective CRF antagonists, antalarmin or astressin-2B 22 minutes before the electrical stimulation. The administration of MOR agonists and MOR antagonists was performed in similar way. When DPPIV inhibition was needed, the slices were pretreated with diprotin A 15 min before the administration of EMs.
Methods
In vitro homogenisation assay
The rats were decapitated and their brains were rapidly removed. The hypothalami were isolated in a Petri dish filled with ice-cold Krebs solution and dissolved in 500 µl acetic acid of 2M concentration in Eppendorf tubes and immersed in boiling water for 5 min and then homogenised with ultrasonic homogeniser (Branson Sonifier 250) at 0°C for 30 sec. The homogenisates were centrifuged twice at 10000 rpm at 4°C for 20 min after of which the supernatants were separated and liophylisated for CRF and AVP determination.
Enzyme-Linked Immuno-Sorbent Assay (ELISA)
For the determination of the amount of CRF in the brain homogenisate we used the mouse/rat CRF-high sensitivity ELISA kit provided by CosmoBio Company, Ltd., Japan. This ELISA kit for determination of mouse/rat CRF is based on a sandwich enzyme (horseradish peroxidase) immunoassay and shows no crossreactivity to UCNs (mouse/rat and human). The CRF concentrations of the extracted samples were corrected for extraction recovery and expressed in ng/ml.
Radio Immuno Assay (RIA)
For the detection of the amount of AVP in the brain homogenisate we used solidphase extraction and competitive radioimmunoassay used for human determination by the Department of Endocrinology, University of Szeged. This assay uses a rabbit anti-AVP antiserum and a radioiodinated AVP [125I] tracer assured by Diagnostics Systems Laboratories Inc., USA. The AVP concentrations of the extracted samples were corrected for extraction recovery and expressed in ng/ml.
Chemical fluorescence assay
The plasma corticosterone concentration was determined by the chemicalfluorescence assay, using ethyl alcohol, methylene chloride and sulfuric acid of analytical grade. The amount of corticosterone secreted was measured by a Hitachi 204-A fluorescent spectrophotometer expressed in terms of 100 mg adrenal tissue, for a period of 1 hour (µg/100 mg hour).
In vitro superfusion assay
The striata and amygdalae were dissected in a Petri dish filled with ice-cold 
Radio scintillation assay
The remnants of superfused brain slices were solubilized in 200 ml of Krebs solution, using an ultrasonic homogenizer (Branson Sonifier 250). The radioactivity in the fractions and the homogenized tissue samples was measured with a liquid scintillation spectrometer (Tri-carb 2100TR, Packard) after the addition of 3 ml of scintillation fluid (Ultima Gold, Packard). The fractional release was calculated as a percentage of the radioactivity (count per minute, CPM) present in the collected sample compared to the total radioactivity of the correspondent tissue.
Statistics
The differences between groups were tested by one-way ANOVA analysis of variance followed by Tukey's post hoc comparison test in cases of homogenisation study and the differences between samples were determined by two-way ANOVA with repeated measures in cases of superfusion study. A probability level of 0.05 or less was accepted as indicating a statistically significant difference.
RESULTS
The hypothalamic CRF and AVP release induced by the UCNs
Equimolar doses (2 µg) of UCNs produced important but different effects on hypothalamic hormone contents; UCN I produced an increase of CRF and AVP, UCN II produced a decrease of CRF, but not AVP amount, UCN III induced an increase of CRF, but not AVP content. However, UCN II and UCN III displayed similar bell-shaped doseresponse curves, with lower doses decreasing and higher doses increasing the CRF levels.
Most evident reductions were assessed with 2 µg of UCN II and 0.5 µg of UCN III. Most significant elevations were achieved with 5 µg of both UCN II and UCN III.
The hypothalamic CRF and AVP release induced by the EMs
Similarly to UCN I, EM1 and EM2 elicited considerably the CRF response, but contrary to the CRFR ligand, the MOR ligands did not influenced significantly the AVP response. The changes of hypothalamic CRF production were mirrored by the corticosterone secretion as well, however only the most effective doses of EM1 (5 µg), EM2 (0.5 µg) and UCN I (2 µg) were tested and represented in the relation of CRF and AVP release. 
The adrenal corticosterone release induced by the UCNs
The effects of the UCNs on striatal and amygdalar neurotransmitters
Our studies demonstrate that both CRF and UCN I increase DA release from the striatum and GABA release from the amygdala following electrical stimulation, through the activation of CRFR1, in accordance with studies indicanting a strong correlation of CRF with DA and GABA in brain regions like the paraventricular and arcuate nuclei of hypothalamus, the ventral tegmental area, the basal ganglia, the basolateral and central nuclei of amygdala. The CRFR2 agonists, UCN II and UCN III, did not influence the neurotransmitter release. This is not surprising since distribution of CRFR2 in the basal ganglia and in the central amygdala is very low. However these results do not rule out the possibility that activation of CRFR2 in other regions of the brain may affect DA or GABA function in the basal ganglia or in the extended amygdala, respectively. 
The effects of the EMs on the HPA neurohormones
Centrally administered EMs did not stimulate the HPA system and had no effect on corticosterone release at doses which were sufficient to activate other physiological systems suggesting that EMs do not play an important role in mediating the stress response or regulating the HPA axis. However parallel studies described EMs having high affinity for the HPA axis. Thus, our colleagues demonstrated that both EM1 and EM2 elicited corticosterone release exhibiting two dose-response curves with similar inverted U-shape but different dose-ranges. These effects are likely to be mediated through CRF, however the participation of other ACTH secretagogues (with the exception of AVP) cannot be fully excuded. Our experiments validated this second opinion, not the first observation. The discrepancies in dose-effect could be explained more likely by the differences in the receptor activation and signal transduction, than the differences in the diffusion and degradation of EMs. Gecse for the technical assistance in the CPM and DPM measurements.
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